Marco Colonna

Marco Colonna is a Italian-born scientist who currently serves on the Scientific Advisory Board at NGM Bio. Marco has also previously worked as a Sr. Scientist at AbbVie, a research associate at Washington University in St. Louis, and a research associate at the National University of Singapore and Seoul National University.

Colonna's work focuses on myeloid cell biology and investigating new targets for cancer immunotherapy. Marco has also done work on tumor-immunophenotyping/immunoprofiling and drug discovery/MoA study. Marco's previous work also includes studying the roles of ILC3 in intestinal immunity and generating multiple genetically engineered mice.

Colonna received their MD from Chonnam National University School of Medicine in 2005. Marco then went on to complete their PhD in immunology from Seoul National University in 2007. After receiving their PhD, they worked as a research associate at Washington University in St. Louis from 2008-2016 before taking their current position at NGM Bio.

Marco Colonna studied immunology at Washington University School of Medicine in St. Louis, earning a Doctor of Philosophy (PhD). Marco also holds a Master of Science (MS) in tumor biology from Seoul National University.